# HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants

> **NCT00125970** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 480 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** VRC-HIVDNA016-00-VP
- **BIOLOGICAL:** VRC-HIVADV014-00-VP
- **BIOLOGICAL:** VRC-HIVDNA016-00-VP placebo
- **BIOLOGICAL:** VRC-HIVADV014-00-VP placebo

## Key facts

- **NCT ID:** NCT00125970
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2008-02
- **Final completion:** 2010-01
- **Target enrollment:** 480 (ACTUAL)
- **Last updated:** 2021-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00125970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00125970, "HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00125970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*